You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
Researchers in Australia are beginning a trial to offer parents-to-be free genetic testing for about 700 conditions, according to the Sydney Morning Herald.
The government-backed project aims to better understand genetic diversity around the South Asian country while helping to inform clinical applications.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
The company is hoping to add outreach to make sure individuals who want counseling get it, and to better understand the reasons why others might not.
The California startup is about to launch its first product, a noninvasive prenatal screening test for recessive single-gene disorders called Unity.
An Australian physician group issues guidelines recommending broader offering of genetic carrier screening, according to the Sydney Morning Herald.
An Australian research team found that population genetic screening for hereditary cancer and for carrier status could be cost-effective.
ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.